EHA 2018 | When is the optimal time to measure minimal residual disease (MRD) in myeloma patients?
Very soon, minimal residual disease (MRD) testing will become a routine part of clinical practice. Therefore, it is important that clinicians understand when and how to use the tests for the optimal management of multiple myeloma (MM) patients. In this interview, Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes when you can use MRD testing throughout the treatment journey in MM, in order to support clinical decision making and monitoring of response. This video was recorded during the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
Get great new content delivered to your inboxSign up